Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line
Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from...
Saved in:
Published in | Journal of Virology Vol. 69; no. 12; pp. 7383 - 7390 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
01.12.1995
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Article Usage Stats
Services
JVI
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
Spotlights in the Current Issue
JVI
About
JVI
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
JVI
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0022-538X
Online ISSN:
1098-5514
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
JVI
.asm.org, visit:
JVI
|
---|---|
AbstractList | The primary receptor for human immunodeficiency virus (HIV) is the CD4 molecule; however, in vitro evidence suggests that a neutral glycolipid, galactosyl ceramide (GalCer) or a derivative molecule, 3' sulfogalactosyl ceramide (GalS), may serve as an alternative receptor for HIV type 1 (HIV-1) in cells of neural and colonic origin. Biochemical studies have demonstrated that recombinant gp120 envelope protein binds to GalCer/GalS in both solid-phase enzyme-linked immunosorbent assay and high-performance thin-layer chromatography overlays. We have used the SK-N-MC cell line, a CD4-negative, GalCer/GalS-positive cell line previously characterized as susceptible to HIV-1 infection, to identify virus isolates with either a positive infection phenotype, HIVHxB2, or a negative infection phenotype, HIV-1(89.6). Using a solid-phase virus binding assay, we determined the level of restriction in HIV-1(89.6) infection to be at the level of virus-glycolipid binding. Furthermore, using HIV-1HxB2-HIV-1(89.6) chimeras, we have identified a 193-amino-acid fragment from the envelope region of HIV-1HxB2 containing the V3, V4, and V5 regions which confers a positive infection phenotype on the HIV-1(89.6) background. Recombinant viruses which separate this 193-amino-acid fragment into two distinct chimeras are each able to confer a positive infection phenotype on the background of HIV89.6, suggesting that a stable GalCer/GalS-envelope interaction is dependent on the conformation of the envelope protein in the context of the viral membrane. Alternatively, the GalCer/GalS-gp120 bond may involve multiple sites on the oligomeric envelope protein. Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy JVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0022-538X Online ISSN: 1098-5514 Copyright © 2014 by the American Society for Microbiology. For an alternate route to JVI .asm.org, visit: JVI The primary receptor for human immunodeficiency virus (HIV) is the CD4 molecule; however, in vitro evidence suggests that a neutral glycolipid, galactosyl ceramide (GalCer) or a derivative molecule, 3' sulfo-galactosyl ceramide (GalS), may serve as an alternative receptor for HIV type 1 (HIV-1) in cells of neural and colonic origin. Biochemical studies have demonstrated that recombinant gp120 envelope protein binds to GalCer/GalS in both solid-phase enzyme-linked immunosorbent assay and high-performance thin-layer chromatography overlays. We have used the SK-N-MC cell line, a CD4-negative, GalCer/GalS-positive cell line previously characterized as susceptible to HIV-1 infection, to identify virus isolates with either a positive infection phenotype, HIV sub(HxB2), or a negative infection phenotype, HIV-1 sub(89.6). Using a solid-phase virus binding assay, we determined the level of restriction in HIV-1 sub(89.6) infection to be at the level of virus-glycolipid binding. Furthermore, using HIV-1 sub(HxB2)-HIV-1 sub(89.6) chimeras, we have identified a 193-amino-acid fragment from the envelope region of HIV-1 sub(HxB2) containing the V3, V4, and V5 regions which confers a positive infection phenotype on the HIV-1 sub(89.6) background. Recombinant viruses which separate this 193-amino-acid fragment into two distinct chimeras are each able to confer a positive infection phenotype on the background of HIV sub(89.6), suggesting that a stable GalCer/GalS-envelope interaction is dependent on the conformation of the envelope protein in the context of the viral membrane. Alternatively, the GalCer/GalS-gp120 bond may involve multiple sites on the oligomeric envelope protein. |
Author | R G Collman F González-Scarano J M Harouse |
AuthorAffiliation | Department of Neurology, School of Medicine University of Pennsylvania, Philadelphia 19104-6146, USA |
AuthorAffiliation_xml | – name: Department of Neurology, School of Medicine University of Pennsylvania, Philadelphia 19104-6146, USA |
Author_xml | – sequence: 1 givenname: J M surname: Harouse fullname: Harouse, J M organization: Department of Neurology, School of Medicine University of Pennsylvania, Philadelphia 19104-6146, USA – sequence: 2 givenname: R G surname: Collman fullname: Collman, R G – sequence: 3 givenname: F surname: González-Scarano fullname: González-Scarano, F |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/7494242$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkktv1DAUhS1UVKaFn4BksYBNPfUjDxupCzQUWiiw4CF2luNcz7hK7CFOgua38edImFEFCImVr_Sdc32PdE7QUYgBEMKMLhnj8vzNl-tloZaML0shBSmFmoBS-T20YFRJkucsO0ILSjknuZBfH6CTlG4pZVlWZMfouMxUxjO-QD-uhtYE7Nt2CLEG562HYHd49N2QcL_bAmbYBwe29zHg6PDHt-Q9ebfCFpomPcd1bI0PaSbrLeN0Eo-xGaGeBgyh73bT0Eds8OplRgKsTe9HOMNr0xjbx7Rrpk2daX0N5-IZTkPjIvkHJNuY_Gz99TFufICH6L4zTYJHh_cUfX51-Wl1RW4-vL5evbghNudlT3htBWWFUIJJLkXl8pI6EFaZylBRmaw2QlaFBVE7BzVnIjdSuELSmlfUGHGKLvZ7t0PVQm3nVKbR2863ptvpaLz-kwS_0es4aiZVUWaT_-nB38VvA6Retz7NKUyAOCRdloWSStH_ClmhyryQ-SSUe6HtYkoduLtjGNVzQfTt6HWhNON6LoieC6LngkzWx7-HuTMeGjHxJ3u-8evNd9-BNqn9a534CWRRyU0 |
CitedBy_id | crossref_primary_10_1007_BF02174000 crossref_primary_10_1007_BF02174004 crossref_primary_10_1007_BF02258044 crossref_primary_10_1016_S0165_0378_98_00059_X crossref_primary_10_1097_00126334_200009010_00001 crossref_primary_10_1021_bi961205g crossref_primary_10_1097_00002030_199804000_00002 crossref_primary_10_1128_JVI_06561_11 crossref_primary_10_1016_j_febslet_2009_11_089 crossref_primary_10_1007_BF02174011 crossref_primary_10_1016_j_ab_2014_08_033 crossref_primary_10_1016_S1367_5931_98_80035_5 crossref_primary_10_1074_jbc_273_14_7967 crossref_primary_10_1007_BF02174014 crossref_primary_10_1039_C6RA06969J crossref_primary_10_1128_JVI_01303_06 crossref_primary_10_4052_tigg_21_255 crossref_primary_10_1016_j_nano_2015_03_008 crossref_primary_10_3389_fmicb_2015_00749 crossref_primary_10_1016_j_virol_2006_07_029 crossref_primary_10_1097_00002030_199906180_00018 crossref_primary_10_1007_BF02174017 crossref_primary_10_1021_bc034156a crossref_primary_10_1128_AAC_48_5_1614_1623_2004 crossref_primary_10_1016_j_abb_2007_01_026 crossref_primary_10_1006_viro_1998_9216 crossref_primary_10_1097_00002030_199711000_00004 crossref_primary_10_1002_bit_20680 crossref_primary_10_1093_glycob_cwj122 crossref_primary_10_1038_nm0197_42 crossref_primary_10_1128_JVI_73_1_638_649_1999 crossref_primary_10_1002_mrd_1122 crossref_primary_10_1089_aid_1997_13_1203 crossref_primary_10_1194_jlr_R026682 crossref_primary_10_1097_01_aids_0000206499_78664_58 crossref_primary_10_1016_j_jconrel_2014_04_033 crossref_primary_10_1097_00042560_200009010_00001 crossref_primary_10_1128_JVI_02496_07 crossref_primary_10_1089_oli_1_1996_6_281 crossref_primary_10_1093_jb_mvs080 crossref_primary_10_1074_jbc_M200554200 crossref_primary_10_1016_S0163_7827_97_00011_8 crossref_primary_10_1016_S1386_6532_01_00193_7 crossref_primary_10_1155_2014_823071 crossref_primary_10_3390_molecules18077912 crossref_primary_10_1074_jbc_272_11_7245 crossref_primary_10_1128_JVI_78_12_6567_6584_2004 crossref_primary_10_1016_S0014_5793_02_03860_7 crossref_primary_10_1006_bbrc_1997_7941 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7U9 H94 7X8 5PM |
DOI | 10.1128/JVI.69.12.7383-7390.1995 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
DatabaseTitleList | CrossRef AIDS and Cancer Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 1098-5514 |
EndPage | 7390 |
ExternalDocumentID | 10_1128_jvi_69_12_7383_7390_1995 7494242 jvi_69_12_7383 |
Genre | Research Support, U.S. Gov't, P.H.S Journal Article Comparative Study |
GrantInformation_xml | – fundername: NINDS NIH HHS grantid: NS-27405 – fundername: NINDS NIH HHS grantid: NS31067 – fundername: NINDS NIH HHS grantid: NS30606 |
GroupedDBID | --- -~X .55 .GJ 0R~ 18M 29L 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 6TJ 85S AAYJJ ABPPZ ACGFO ACNCT ADBBV AENEX AFFNX AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF D0S DIK E3Z EBS ECM EIF EJD F20 F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 MVM N9A NPM O9- OHT OK1 P2P RHF RHI RNS RPM RSF TR2 UCJ UPT VH1 W2D W8F WH7 WOQ X7M Y6R YQT ZGI ZXP ~02 ~KM AAYXX CITATION 7U9 H94 7X8 5PM |
ID | FETCH-LOGICAL-c527t-2dc301639318283bf570fe3c9aba03ba4da38b6ce3dffed2135a83f680d2b0aa3 |
IEDL.DBID | RPM |
ISSN | 0022-538X |
IngestDate | Tue Sep 17 21:12:37 EDT 2024 Thu Oct 24 23:46:09 EDT 2024 Fri Oct 25 01:21:32 EDT 2024 Thu Sep 12 16:49:34 EDT 2024 Sat Sep 28 07:32:52 EDT 2024 Wed May 18 15:27:50 EDT 2016 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c527t-2dc301639318283bf570fe3c9aba03ba4da38b6ce3dffed2135a83f680d2b0aa3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://jvi.asm.org/content/jvi/69/12/7383.full.pdf |
PMID | 7494242 |
PQID | 16975685 |
PQPubID | 23462 |
PageCount | 8 |
ParticipantIDs | pubmed_primary_7494242 pubmedcentral_primary_oai_pubmedcentral_nih_gov_189674 highwire_asm_jvi_69_12_7383 crossref_primary_10_1128_jvi_69_12_7383_7390_1995 proquest_miscellaneous_77698990 proquest_miscellaneous_16975685 |
PublicationCentury | 1900 |
PublicationDate | 1995-12-01 |
PublicationDateYYYYMMDD | 1995-12-01 |
PublicationDate_xml | – month: 12 year: 1995 text: 1995-12-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of Virology |
PublicationTitleAlternate | J Virol |
PublicationYear | 1995 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | 8497073 - J Virol. 1993 Jun;67(6):3649-52 1548783 - J Virol. 1992 Apr;66(4):2577-82 7983725 - J Virol. 1995 Jan;69(1):320-5 1282933 - J Neurosci Res. 1992 Dec;33(4):513-8 8096089 - Science. 1993 Mar 19;259(5102):1749-54 8160767 - Am J Pathol. 1994 Apr;144(4):659-66 1367682 - Curr Opin Biotechnol. 1991 Aug;2(4):622-33 2536142 - Nature. 1989 Jan 26;337(6205):368-70 2786088 - J Virol. 1989 Jun;63(6):2527-33 7884870 - J Virol. 1995 Apr;69(4):2233-9 1378511 - J Virol. 1992 Aug;66(8):4848-54 7888115 - AIDS. 1994 Dec;8(12):1669-74 8411372 - J Virol. 1993 Nov;67(11):6707-15 7045870 - Proc Natl Acad Sci U S A. 1982 Apr;79(8):2709-13 2677235 - J Gen Virol. 1989 Oct;70 ( Pt 10):2653-60 1551875 - J Biol Chem. 1992 Apr 5;267(10):6664-71 7909962 - Science. 1994 May 20;264(5162):1161-2; author reply 1162-5 7809077 - Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12559-63 3094962 - Cell. 1986 Nov 7;47(3):333-48 1857969 - Science. 1991 Jul 19;253(5017):320-3 2571666 - J Exp Med. 1989 Oct 1;170(4):1149-63 7687303 - J Virol. 1993 Aug;67(8):4785-96 7903479 - Science. 1993 Dec 24;262(5142):2045-50 2578615 - Nature. 1985 Jan 24-30;313(6000):277-84 6977490 - Immunogenetics. 1982;15(2):199-206 7504741 - J Virol. 1994 Jan;68(1):469-84 8145919 - Neurology. 1994 Mar;44(3 Pt 1):481-7 3472222 - Proc Natl Acad Sci U S A. 1987 May;84(10):3526-30 8184533 - Virology. 1994 Jun;201(2):206-14 1995952 - J Virol. 1991 Mar;65(3):1543-50 7815477 - J Virol. 1995 Feb;69(2):1013-8 1727490 - J Virol. 1992 Jan;66(1):305-9 1404602 - J Virol. 1992 Nov;66(11):6547-54 7853514 - J Virol. 1995 Mar;69(3):1755-61 1920627 - J Virol. 1991 Nov;65(11):6094-100 2293663 - J Virol. 1990 Jan;64(1):215-21 8057468 - J Virol. 1994 Sep;68(9):5890-8 1673040 - Virology. 1991 Apr;181(2):703-15 2172833 - Nature. 1990 Nov 1;348(6296):69-73 7856100 - Virology. 1995 Feb 1;206(2):878-84 2304148 - J Virol. 1990 Mar;64(3):1383-7 1279195 - J Virol. 1992 Dec;66(12):6997-7004 2683359 - Virology. 1989 Nov;173(1):178-87 7831820 - Virology. 1995 Jan 10;206(1):646-50 8424881 - Biotechniques. 1993 Jan;14(1):70-81 2600978 - J Neurosci Res. 1989 Dec;24(4):548-57 2479771 - J Virol. 1989 Dec;63(12):5054-61 8464878 - Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2700-4 1871126 - Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7131-4 2200889 - J Virol. 1990 Sep;64(9):4468-76 1433527 - J Virol. 1992 Dec;66(12):7517-21 2002539 - J Virol. 1991 Apr;65(4):1710-8 1905842 - Science. 1991 Jul 5;253(5015):71-4 |
References_xml | |
SSID | ssj0014464 |
Score | 1.7736197 |
Snippet | Article Usage Stats
Services
JVI
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley... The primary receptor for human immunodeficiency virus (HIV) is the CD4 molecule; however, in vitro evidence suggests that a neutral glycolipid, galactosyl... |
SourceID | pubmedcentral proquest crossref pubmed highwire |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 7383 |
SubjectTerms | AIDS/HIV Antigens, CD - genetics Antigens, CD - physiology Base Sequence Binding Sites CD4 Antigens - genetics CD4 Antigens - physiology Cell Line Chromatography, High Pressure Liquid DNA Primers DNA, Viral - analysis DNA, Viral - isolation & purification Enzyme-Linked Immunosorbent Assay Galactosylceramides - analysis Galactosylceramides - physiology HeLa Cells HIV Envelope Protein gp120 - metabolism HIV-1 - genetics HIV-1 - physiology human immunodeficiency virus Humans Kinetics Molecular Sequence Data Neuroblastoma Phenotype Polymerase Chain Reaction Receptors, Virus - analysis Receptors, Virus - physiology Species Specificity Sulfoglycosphingolipids Tumor Cells, Cultured |
Title | Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3' sulfo-galactosyl ceramide-positive cell line |
URI | http://jvi.asm.org/content/69/12/7383.abstract https://www.ncbi.nlm.nih.gov/pubmed/7494242 https://search.proquest.com/docview/16975685 https://search.proquest.com/docview/77698990 https://pubmed.ncbi.nlm.nih.gov/PMC189674 |
Volume | 69 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBZNIJBL6St0mz50KPRSrd969Fa2DWlKQqFN2ZuQLClxWdvLenchv61_riPZDt2QXnozjGzLzEj6ZvzNDEJvhYexhbGkUJkmOTeOKOEEoYwxgCMuj01gW1zQ08v8bF7Mh6SwbqBVNqWups2injbVdeBWLusyGnli0bfzWcIFZXm0h_bAPkcPffhzAO5NPlYIh8U8H9k7KY_Ofn6ZUuGjfwz8MsLA3ffJesUhOmC5yNM83T2cxoLB94HPuxzKvw6lk0fo4YAm8cd-1o_RA9s8QQd9f8mbp-h3CNHjyueAtMb6YhE-0xJvq9Wmwz76ihM80rEa3Dr8_Su5IOcz7OP53Qds2lpVTeclV8skjWEwbGdba-ACh54kcLFuscKzTzlp7FUoI_4ew7Hj-_h0Nwt40krVlbFR9g53m4VryT1C0nPHtja8GHvo-wxdnnz-MTslQ7cGUhYpW5PUlLBZAOCBXQIwi3YFi53NSqG0ijOtcqMyrmlpM-OcNWmSFYpnjvLYpDpWKjtC-03b2OcIC_DaGGAzmpQC_E-qlOVOc67L0rmSZxOUjGqSy74ohwzOTMrlr20lqZBJKr2SpVey9EqeoONRn1J19Z1xE_RmVLGE9eW_VTW23XQyoYIVlBf_HsGYb8Ip4gk66k3idk6DVU0Q3bGVW7kv7b0rAYsPJb57C3_xvzceo8OQeh9oNy_R_nq1sa8APK3167Ba_gBMLxqe |
link.rule.ids | 230,315,730,783,787,888,27936,27937,53804,53806 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZg0Yq9IF4rwgLrAxIX3ObpBzdUWHUfrZDYRb1ZTmwvQW1SNW2l_W38OcZOsqKr5cIt0jiJoxnb30y-mUHovXAwNtOGZCrJScq1JUpYQShjDOCITUPt2RZTOr5Kz2bZrEsKazpaZVXk5aCaLwZV-dNzK5eLYtjzxIbfJqOIC8rS4UP0CJZrmPY-evfvAByctK8RDvJZz9-J-fDsx-mAChf_Y-CZEQYOv0vXyw7QPktFGqfx7vHUlwy-D37eZVH-dSydPEVPOjyJP7fzfoYemOo52m87TN68QL99kB6XLguk1saVi3C5lnhbrjYNdvFXHOGekFXh2uLv52RKJiPsIvrNJ6zrhSqrxkmul1EcwmDY0LZGwwX2XUngYl1jhUdfUlKZa19I_COGg8d18mlu5vCklVqU2gyTD7jZzG1N7hGSlj22Nf7F2IHfl-jq5OvlaEy6fg2kyGK2JrEuYLsAyAP7BKCW3GYstCYphMpVmOQq1SrhOS1Moq01Oo6STPHEUh7qOA-VSg7RXlVX5hXCAvw2BuiMRoUAD5QqZbjNOc-LwtqCJwGKejXJZVuWQ3p3Juby17aUVMgolk7J0ilZOiUH6KjXp1TN4s64AB33Kpawwty3qsrUm0ZGVLCM8uzfIxhzbThFGKDD1iRu59RZVYDojq3cyl1x710J2Lwv8t3a-Ov_vfEYPR5fTi7kxen0_Agd-ER8T8J5g_bWq415C1Bqnb_zK-cPSHId9A |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKUVEviFfVUKA-IHHBm7cf3NCWVR90VQmK9mY5sV2CdpPVZnel_jb-HGNnU7FVuXCLNE7iaMb2N5NvZhB6LxyMzbUhuUoLknFtiRJWEMoYAzhis0h7tsWYnl5n55N8soN4nwvjSftlUQ3q6WxQVz89t3I-K8OeJxZeXQ5jLijLwrm24SP0GJZsRHs_ffP_AJycrK8TDvJJz-FJeHj-42xAhYsBMvDOCAOn36Xs5ftoj2UiS7Jk-4jqywY_BEHvMyn_OppGz9DTDabEn7u5P0c7pn6B9rouk7cv0W8fqMeVywRptHElI1y-JV5Xi1WLXQwWx7gnZdW4sfjbBRmTyyF2Uf32E9bNTFV16yQ38ziJYDBsamuj4QL7ziRwsWywwsOTjNTmxhcT_4jh8HHdfNrbKTxpoWaVNmH6AberqW3IA0LSMcjWxr8YOwD8Cl2PvnwfnpJNzwZS5glbkkSXsGUA7IG9ApBLYXMWWZOWQhUqSguVaZXygpYm1dYancRprnhqKY90UkRKpQdot25qc4iwAN-NAUKjcSnAC6VKGW4LzouytLbkaYDiXk1y3pXmkN6lSbj8ta4kFTJOpFOydEqWTskBOur1KVU7uzcuQMe9iiWsMvetqjbNqpUxFSynPP_3CMZcK04RBeigM4m7OW2sKkB0y1bu5K7A97YE7N4X-u7s_PX_3niMnlydjOTXs_HFEdr3ufieh_MG7S4XK_MW0NSyeOcXzh9Vtx8H |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+immunodeficiency+virus+type+1+infection+of+SK-N-MC+cells%3A+domains+of+gp120+involved+in+entry+into+a+CD4-negative%2C+galactosyl+ceramide%2F3%27+sulfo-galactosyl+ceramide-positive+cell+line&rft.jtitle=Journal+of+virology&rft.au=Harouse%2C+J+M&rft.au=Collman%2C+R+G&rft.au=Gonz%C3%A1lez-Scarano%2C+F&rft.date=1995-12-01&rft.issn=0022-538X&rft.volume=69&rft.issue=12&rft.spage=7383&rft.epage=7390&rft_id=info:doi/10.1128%2FJVI.69.12.7383-7390.1995&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon |